Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes

Executive Summary

Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but a negative JAMA editorial is another knock on the PCSK9 inhibitor class.


Related Content

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
Merck Calls It Quits On Anacetrapib
Sanofi 2Q: Dupixent's First Set Of Sales Are On Track
Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?
Amgen Faces New ICER Roadblock To Repatha Reimbursement
Praluent Injunction Goes Unmentioned At PCSK9 Patent Case Appeal
Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Time, And Price, Are Right To Prescribe Statins To the Masses


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts